Added to YB: 2025-05-08
Pitch date: 2025-05-06
NVO [bullish]
Novo Nordisk A/S
-29.48%
current return
Author Info
I write about investing, decision-making, and the power of compounding in both wealth and life. My focus is on rational investing, long-term thinking, and avoiding the emotional traps that derail most investors. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 435.90
Price Target
861.00 (+180%)
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
growth
Novo Nordisk – A Victim of Its Own Hype
NVO: Obesity drug leader at attractive P/E, with 22% YoY revenue growth. CagriSema trial disappointed (13.7% vs expected 15% weight loss), causing 60% drop. Market misinterpreting competition - obesity isn't winner-takes-all. DCF shows 11-15% FCF growth needed to justify price. Headwinds: Eli Lilly gaining share, compounders (30-40% market), pricing pressure. Catalysts: FDA ending compounding exceptions, Hims partnership.
Read full article (11 min)